Corrigendum to "Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's antiseizure efficacy" [Neuropharmacology 143 (2018) 186–204]. (December 2018)

Record Type:
Journal Article
Title:
Corrigendum to "Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's antiseizure efficacy" [Neuropharmacology 143 (2018) 186–204]. (December 2018)
Main Title:
Corrigendum to "Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's antiseizure efficacy" [Neuropharmacology 143 (2018) 186–204]
Authors:
Brandt, Claudia
Seja, Patricia
Töllner, Kathrin
Römermann, Kerstin
Hampel, Philip
Kalesse, Markus
Kipper, Andi
Feit, Peter W.
Lykke, Kasper
Toft-Bertelsen, Trine Lisberg
Paavilainen, Pauliina
Spoljaric, Inkeri
Puskarjov, Martin
MacAulay, Nanna
Kaila, Kai
Löscher, Wolfgang
Abstract:
Is Part Of:
Neuropharmacology. Volume 143(2018)
Journal:
Neuropharmacology
Issue:
Volume 143(2018)
Issue Display:
Volume 143, Issue 2018 (2018)
Year:
2018
Volume:
143
Issue:
2018
Issue Sort Value:
2018-0143-2018-0000
Page Start:
349
Page End:
350
Publication Date:
2018-12
Subjects:
Neuropsychopharmacology -- Periodicals
Autonomic Agents -- Periodicals
Neuropsychopharmacologie -- Périodiques
Neuropsychopharmacology
Periodicals
Electronic journals
615.78
Journal URLs:
http://www.sciencedirect.com/science/journal/00283908 ↗
http://www.elsevier.com/journals ↗
DOI:
10.1016/j.neuropharm.2018.10.012 ↗
Languages:
English
ISSNs:
0028-3908
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - 6081.517500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
8753.xml